Paraskar G, Bhattacharya S, Kuttiappan A. The Role of Proteomics and Genomics in the Development of Colorectal Cancer Diagnostic Tools and Potential New Treatments.
ACS Pharmacol Transl Sci 2025;
8:1227-1250. [PMID:
40370990 PMCID:
PMC12070319 DOI:
10.1021/acsptsci.4c00686]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2024] [Revised: 03/14/2025] [Accepted: 04/03/2025] [Indexed: 05/16/2025]
Abstract
The complex molecular mechanisms involving genetic and epigenetic modifications contribute to colorectal cancer (CRC), which remains a significant threat to world health. This review elucidates the role of proteomics and genomics in the progression, diagnosis, and treatment of colorectal cancers. All potential key pathways involved in CRC, including WNT, MAPK, PI3K, and TGF-β pathways, are reviewed with a systematic analysis, concluding with their involvement in tumorigenesis and therapeutic resistance. Emerging next-generation sequencing technologies revealed critical mutations that are relevant to CRC development. Proteomics has contributed to identifying biomarkers and post-translational modifications that hold promise for targeted therapies. Recent technological advances have provided functional insights into protein signaling networks and pathways through mass spectrometry and integrated proteogenomic approaches. This work emphasizes biomarker-driven translational efforts that integrate genomic insights with protein expression profiles to refine personalized treatments. The application of innovations in liquid biopsy and computational biology advocates for precision medicine paths to improve the outcomes for CRC. Now, pharmacoproteomics offers novel domains for drug discovery and resistance management and serves as a foundation for comprehensive CRC treatment paradigms.
Collapse